The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 22nd Feb 2013 07:12

Antofagasta: RBC upgrades from underperform to outperform.Ashmore Group: Citigroup raises target price from 330p to 355p upgrading to neutral. JP Morgan ups target price from 361p to 413p and maintains a neutral rating.Babcock International: Citigroup revises target price from 965p to 1185p and keeps its buy recommendation.BAE Systems: Deutsche Bank takes target price from 360p to 375p maintaining a buy recommendation. JP Morgan increases target price from 330p to 360p and retains a neutral rating.Barclays: Investec shifts target price from 340p to 345p and upgrades from hold to buy.BP: Canaccord Genuity downgrades from buy to hold with a target price of 500p.Bumi: JP Morgan reiterates underweight. Liberum reinitiates coverage at buy.British Sky Broadcasting: HSBC ups target price from 520p to 600p keeping an underweight rating.Capita Group: Citigroup moves target price from 870p to 990p, while leaving its buy recommendation unchanged.Chariot Oil & Gas: Jefferies ups target price from 36p to 50p and upgrades from hold to buy. Merchant Securities cuts target price from 29.20p to 20.60p, while reiterating a hold recommendation.CSR: UBS raises target price from 330p to 450p, while retaining a neutral rating. Deutsche Bank revises target price from 255p to 300p, while staying with its sell recommendation. JP Morgan takes target price from 450p to 475p and reiterates an overweight rating. Canaccord Genuity moves target price from 370p to 475p and keeps a buy recommendation.Drax Group: Goldman Sachs downgrades from buy to neutral.Filtrona: UBS increases target price from 600p to 660p and keeps a buy recommendation.Fresnillo: Societe Generale initiates with a target price of 1200p and a sell recommendation.GlaxoSmithKline: Jefferies moves target price from 1500p to 1550p and maintains a hold recommendation.Go-Ahead Group: HSBC revises target price from 1415p to 1485p, while staying with an overweight rating.G4S: HSBC shifts target price from 260p to 270p and downgrades to underweight.Halfords Group: UBS lowers target price from 290p to 280p and retains a sell recommendation.HSBC Holdings: Credit Suisse moves target price from 750p to 760p and keeps an outperform rating.Informa: Deutsche Bank shifts target price from 600p to 620p and leaves its buy recommendation unaltered. Citigroup takes target price from 520p to 550p reiterating a buy rating. Westhouse Securities ups target price from 493p to 525p and upgrades from neutral to add. Canaccord Genuity raises target price from 500p to 560p maintaining its buy recommendation. Investec increases target price from 495p to 520p keeping a hold recommendation.InterContinental Hotels Group: Citigroup increases target price from 1900p to 2200p retaining its buy recommendation.Interserve: Westhouse Securities raises target price from 432p to 537p, while downgrading from buy to add.Johnson Matthey: Morgan Stanley reduces target price form 2300p to 2200p retaining an underweight rating.Kingfisher: HSBC cuts target price from 340p to 335p and keeps its overweight rating.Lancashire: Nomura increases target price from 826p to 906p not altering its neutral rating.Millennium & Copthome: Credit Suisse moves target price from 524p to 542p and retains its neutral rating.Mondi: UBS ups target price from 720p to 840p, while leaving its neutral rating unchanged.Netplay: Merchant Securities initiates with a target price of 20p and a buy recommendation.New World Resources: JP Morgan shifts target price from 150p to 160p leaving its underweight rating unaltered.Old Mutual: JP Morgan raises target price from 186p to 209p, while downgrading to neutral.Pendragon: Panmure Gordon shifts target price from 15p to 19p and still recommends selling.Restaurant Group: Citigroup revises target price from 400p to 450p, while the buy recommendation is kept.REXAM: Credit Suisse shifts target price from 545p to 555p and stays with its neutral rating. Oriel Securities ups target prcie from 540p to 570p maintaining a buy recommendation.Sainsbury: Citigroup raises target price from 315p to 385p upgrading to buy.Serco Group: Citigroup shifts target price from 670p to 680p reiterating a buy recommendation.Shire: Morgan Stanley moves target price from 2350p to 2400p keeping an overweight rating.Spectris: N+1 Singer takes target price from 2135p to 2415p, while reiterating a hold recommendation. Investec ups target price from 2400p to 2575p and stays with its hold rating.Sports Direct International: Citigroup increases target price from 470p to 530p and still recommends buying.Whitbread: Citigroup raises target price from 2400p to 2675p and leaves its neutral rating unchanged. JP Morgan revises target price from 2650p to 2700p maintaining an overweight rating. Panmure Gordon ups target price from 1994p to 2500p, while reiterating a hold recommendation.William Hill: Jefferies raises target price from 370p to 500p keeping a buy recommendation.Xaar: Investec starts with a target price of 350p and a buy recommendation.
More News
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.